Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in invasive breast cancer in women.
Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in invasive breast cancer in women.
复制标题
DOI：
10.5114/aoms.2012.31010
复制
发表时间：
2013-06-20
期刊：
影响因子：
--
通讯作者：
Kozłowski W
中科院分区：
文献类型：
--
作者：
Badowska-Kozakiewicz AM;Sobol M;Patera J;Kozłowski W
雌激素受体（ER）、孕激素受体（PR）和人表皮生长因子受体2（HER-2）的表达在乳腺癌的生物学中起着至关重要的作用。HER-2/neu基因在15-30%的浸润性乳腺癌中扩增和过表达。HER-2阳性乳腺癌的预后比HER-2阴性乳腺癌差，并且具有独特的临床特征。本研究的目的是评估浸润性乳腺癌患者癌组织中HER 2的表达与肿瘤类型、组织学分级、肿瘤大小、淋巴结状态以及雌激素受体和孕激素受体表达的相关性。福尔马林固定，石蜡包埋组织从40例浸润性HER-2阳性乳腺癌和191例HER-2阴性乳腺癌患者在这项研究中使用。使用测试HerceptTest™ DAKO测定HER 2表达。231例乳腺癌中，浸润性小叶癌18例，浸润性导管癌213例。60%的HER-2阳性乳腺癌为ER阳性，而HER-2阴性组为77%（p = 0.002）。PR的表达在43%的HER-2阳性乳腺癌和72%的HER-2阴性肿瘤中观察到（p = 0.003）。在60%的雌激素受体阳性患者中检测到HER 2蛋白的过度表达，这可能使这些患者的预后恶化。确定乳腺癌患者中的HER 2过表达，允许确定具有较差预后的一组患者。
Estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER-2) expression are crucial in the biology of breast carcinoma. HER-2/neu gene is amplified and overexpressed in 15-30% of invasive breast cancers. HER-2-positive breast cancers have worse prognosis than HER-2 negative tumors and possess distinctive clinical features. The aim of this study was to assess the expression of HER2 in cancer tissue of patients with invasive breast cancer in correlation with tumor type, histological grade, tumor size, lymph node status, and expression of estrogen receptor and progesterone receptor. Formalin-fixed, paraffin-embedded tissues from 40 patients with invasive HER-2-positive breast cancer and from 191 patients with HER-2-negative breast cancer were used in this study. HER2 expression was determined using the test HerceptTest™ DAKO. Among 231 cases of breast cancer, 18 invasive lobular carcinomas and 213 invasive ductal carcinomas were diagnosed. Sixty percent of HER-2-positive breast cancers were ER-positive compared with 77% in the HER-2-negative group (p = 0.002). The expression of PR was observed in 43% of HER-2-positive breast cancers and in 72% of HER2-negative tumors (p = 0.003). Excessive expression of HER2 protein was detected in 60% of patients positive for estrogen receptors, which may worsen prognosis in these patients. Determination of HER2 overexpression in breast cancer patients, allows for a determination of a group of patients with a worse prognosis.
登录
查看更多内容
影响因子：
3.5
作者：
RAVDIN, PM;CHAMNESS, GC
通讯作者：
CHAMNESS, GC
影响因子：
3.4
作者：
Huang, HJ;Neven, P;Christiaens, MR
通讯作者：
Christiaens, MR
影响因子：
7.4
作者：
Almasri, NM;Al Hamad, M
通讯作者：
Al Hamad, M
影响因子：
3.3
作者：
Mack, L;Kerkvliet, N;OMalley, FP
通讯作者：
OMalley, FP
影响因子：
56.9
作者：
SLAMON, DJ;CLARK, GM;MCGUIRE, WL
通讯作者：
MCGUIRE, WL